SMN2 and Onset: A prime example for the therapeutic potential is the steric hindrance of an intronic SMN2 silencer element using an antisense oligonucleotide that boosts the inclusion of Exon 7 in SMN2 mRNA and effectively treats infantile-onset spinal muscular atrophy [36,37].